Galmed Pharmaceuticals
GLMD
12 hedge funds and large institutions have $113K invested in Galmed Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
96% more capital invested
Capital invested by funds: $57.6K → $113K (+$55.3K)
0.14% more ownership
Funds ownership: 0.38% → 0.52% (+0.14%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$90.9K |
| 2 |
Morgan Stanley
New York
|
+$7.94K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$10K |
| 2 |
Two Sigma Advisers
New York
|
-$7.71K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$2.18K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$724 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Walleye Capital
New York
| $83.1K | +$90.9K | +20,715 | +592% |
|
|
CH
2
CVI Holdings
Wilmington,
Delaware
| $13.5K | -$10K | -2,285 | -37% |
|
|
3
Morgan Stanley
New York
| $9.96K | +$7.94K | +1,810 | +150% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $3.33K | +$4.25K | +969 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $2.84K | -$2.18K | -498 | -37% |
|
|
6
UBS Group
Zurich,
Switzerland
| $77 | -$724 | -165 | -88% |
|
7
Wells Fargo
San Francisco,
California
| $56 | – | – | – |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $46 | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $14 | – | – | – |
|
|
AF
10
Allworth Financial
Folsom,
California
| $6 | – | – | – |
|
|
EWP
11
Elevation Wealth Partners
Santa Rosa,
California
| $2 | – | – | – |
|
|
12
Two Sigma Advisers
New York
| – | -$7.71K | -1,856 | Closed |
|
GLMD Hedge Fund Activity: Q2 2024 in Review
12 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2024, worth a combined $113K — up 96% from $57.6K a quarter earlier.
Fund positioning in GLMD was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Walleye Capital, adding an estimated $90.9K. The largest seller was CVI Holdings, cutting an estimated $10K.
- 12 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $113K of Galmed Pharmaceuticals stock for Q2 2024, up 96% quarter-over-quarter.
- 1 fund opened new Galmed Pharmaceuticals positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2024 was Walleye Capital, an estimated $90.9K added.
- The largest Galmed Pharmaceuticals seller in Q2 2024 was CVI Holdings, an estimated $10K sold.
Based on aggregated 13F filings for Q2 2024.